NS Pharma, Inc.
9 Campus Drive
3rd Floor
Parsippany
New Jersey
07054
United States
Tel: 973-285-7010
Fax: 973-267-4240
Website: http://www.nippon-shinyaku.co.jp/
15 articles with NS Pharma, Inc.
-
VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the Child Neurology Society Annual Meeting
9/22/2021
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension (up to 192 weeks) of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the Child Neurology Society 50th Annual Meeting.
-
VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the World Muscle Society 2021 Virtual Conference
9/17/2021
NS Pharma, Inc. announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension (up to 192 weeks) of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the World Muscle Society 2021 Virtual Conference being held September 20–24.
-
VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Presented at the PPMD 2021 Virtual Annual Conference
7/1/2021
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced that new long-term efficacy and safety data based on interim analyses at 109 weeks from the open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection were presented at the PPMD 2021 Annual Conference.
-
Webcast of VILTEPSO® (viltolarsen) injection: Long-Term Data Scheduled for Presentation at the PPMD 2021 Virtual Annual Conference
6/21/2021
NS Pharma, Inc. announces a webcast during the PPMD 2021 Virtual Annual Conference held from June 23 to 26 .
-
VILTEPSO® (viltolarsen) injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual Conference
5/12/2021
NS Pharma, Inc., a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., announced that new, long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO® injection will be presented at the PPMD 2021 Annual Conference being held virtually from June 23-26.
-
NS Pharma's VILTEPSO® (viltolarsen) Receives Permanent J-code from Centers for Medicare and Medicaid Services
4/1/2021
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Shigenobu Maekawa), announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for VILTEPSO® (viltolarsen) injection is effective today.
-
VILTEPSO™ (viltolarsen) injection Now Commercially Available in the U.S.
8/19/2020
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka ), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Shigenobu Maekawa ), announced today that VILTEPSO™ (viltolarsen) injection is now commercially available in the U.S. On August 12, 2020 , the U.S. Food & Drug Administration (FDA) approve
-
The U.S. Food and Drug Administration (FDA) approved another therapy for Duchenne muscular dystrophy (DMD), this time NS Pharma’s Viltepso (viltolarsen).
-
NS Pharma's VILTEPSO™ (viltolarsen) injection Now FDA-Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy
8/12/2020
Patients taking VILTEPSO showed an increase in dystrophin expression to an average of 5.9% of normal after 20-24 weeks of treatment.
-
NS Pharma Announces Launch of Patient Support Hub
7/7/2020
NS Pharma, Inc., a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., announced the launch of NS Support for patients with Duchenne muscular dystrophy and their healthcare providers.
-
NS Pharma Announces Publication of Clinical Trial Data for Viltolarsen in DMD Patients in JAMA Neurology
5/26/2020
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President Shigenobu Maekawa), announced today that JAMA Neurology has published results from a clinical trial of viltolarsen, an investigational agent being evaluated in Duchenne muscular dystrophy (DMD) patients who are amenable to exon 53 skipping therapy.
-
NS Pharma, Inc. To Present At J.P. Morgan Healthcare Conference
1/6/2015
-
NS Pharma, Inc. To Present At J.P. Morgan Healthcare Conference
1/6/2015
-
NS Pharma, Inc. Celebrates 20th Anniversary Of Initial Public Offering With NASDAQ Opening Bell Ceremony
5/27/2014
-
The Day In Review: Preos From NS Pharma, Inc. Gets Approvable Letter
3/10/2006